Abionyx Pharma: net loss doubled to €4.81 million in first half, cash position of €26.9 million
Abionyx Pharma published its first half 2026 financial statements on September 23, 2026. Net loss reached €4.81 million, compared to €2.31 million a year earlier, a gap stemming primarily from a negative financial result linked to bond debt.
At the same time, the biotechnology company based in Balma has cash and equivalents of €26.9 million as of end June, following the financing operation announced on June 18, 2026.
Net loss doubled due to financial result
The group reported consolidated revenue of €1.93 million in the first half of 2026, compared to €2.12 million a year earlier. This income comes solely from contract research activity in ophthalmology from its subsidiary Iris Pharma, as the activity dedicated to therapies for sepsis and LCAT deficiency (Norum disease) has not yet generated revenue.
Research and development expenses stood at €570 thousand, compared to €692 thousand on June 30, 2025. Administrative and commercial expenses reached €1,807 thousand, compared to €1,876 thousand a year earlier. Operating loss came to €2.27 million, compared to a loss of €2.33 million in the first half of 2025.
The main difference lies in the financial result, a loss of €2.54 million compared to a profit of €32 thousand a year earlier. The company attributes this result to the fair value measurement of financial debt related to Fenja bond obligations, with the recognition of a financial charge of €1.6 million, as well as financial costs related to the issuance of these bonds. Net loss thus stands at €4.81 million, compared to €2.31 million in the first half of 2025.
Cash position of €26.9 million following the June financing operation
As of end June 2026, consolidated cash and cash equivalents amounted to €26.9 million, compared to €3.38 million on June 30, 2025. This increase follows the financing operation announced on June 18, 2026 and occurs before the collection of research tax credits and subsidies from the France 2030 plan.
Cash flows related to financing activities reached €25.44 million during the half-year, compared to €2.00 million a year earlier. Cash flows related to operating activities stood at an outflow of €2.04 million, compared to an outflow of €1.70 million in the first half of 2025.
The company also indicates that it has been awarded the i-Démo call for projects under the France 2030 plan and has secured €8.7 million in public funding dedicated to combating sepsis, of which €6.2 million remains to be received.
Priority given to execution of sepsis and LCAT deficiency programs
The company indicates it remains focused on executing its strategy and implementing its programs, in particular GMP-compliant production for sepsis and LCAT deficiency, as well as preparing the next regulatory steps related to the phase 2b trial in sepsis.
On the commercial activity front, Abionyx Pharma anticipates that Iris Pharma's revenue for 2026 will remain broadly stable compared to 2025. The half-yearly financial report as of June 30, 2026 has been made available to the public and published on the website of the Financial Market Authority.
